biostudies-literatureStevens TWTakedaNIDDK NIH HHSShire2333-2342https://www.ebi.ac.uk/biostudies/studies/S-EPMC8140548biostudies-literatureUnknown19(11)<h4>Background & aims</h4>Histologic features of inflammation (histologic inflammation) are associated with clinical relapse in patients with ulcerative colitis (UC). Concentration of fecal calprotectin (FC) can be used to identify patients with mucosal inflammation. We aimed to assess the accuracy of FC measurements in identifying patients with histologic inflammation and to develop a model to predict outcomes of therapy.<h4>Methods</h4>We performed a post hoc analysis of data from a phase 4 trial of the efficacy of multimatrix mesalamine in patients with mild to moderate UC (the MOMENTUM trial). We obtained clinical, endoscopic, and histologic data from week 8 (n = 639) and week 52 (n = 373) of the trial. We used area under the receiver operating characteristic curves to determine the acClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationDiagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.PMC8140548R01 DK061931R01 DK068271de Hertogh GD'Haens GRTurner JRRubin DTGecse KStevens TWfalseDiagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.<h4>Background & aims</h4>Histologic features of inflammation (histologic inflammation) are associated with clinical relapse in patients with ulcerative colitis (UC). Concentration of fecal calprotectin (FC) can be used to identify patients with mucosal inflammation. We aimed to assess the accuracy of FC measurements in identifying patients with histologic inflammation and to develop a model to predict outcomes of therapy.<h4>Methods</h4>We performed a post hoc analysis of data from a phase 4 trial of the efficacy of multimatrix mesalamine in patients with mild to moderate UC (the MOMENTUM trial). We obtained clinical, endoscopic, and histologic data from week 8 (n = 639) and week 52 (n = 373) of the trial. We used area under the receiver operating characteristic curves to determine the ac2021-01-01T00:00:00Z2021 Nov2026-05-28T01:03:38.663Z2025-04-19T22:45:23.365ZS-EPMC81405483280100810.1016/j.cgh.2020.08.019